Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) suppress normal hematopoietic activity in part by enabling a pathogenic inflammatory milieu in the bone marrow. In this report, we show that elevation of angiopoietin-1 in myelodysplastic CD34+ stem-like cells is associated with higher...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Res
Autori principali: Bachegowda, Lohith, Morrone, Kerry, Winski, Shannon L., Mantzaris, Ioannis, Bartenstein, Matthias, Ramachandra, Nandini, Giricz, Orsi, Sukrithan, Vineeth, Nwankwo, George, Shahnaz, Samira, Bhagat, Tushar, Bhattacharyya, Sanchari, Assal, Amer, Shastri, Aditi, Gordon-Mitchell, Shanisha, Pellagatti, Andrea, Boultwood, Jacqueline, Schinke, Carolina, Yu, Yiting, Guha, Chandan, Rizzi, James, Garrus, Jennifer, Brown, Suzy, Wollenberg, Lance, Hogeland, Grant, Wright, Dale, Munson, Mark, Rodriguez, Mareli, Gross, Stefan, Chantry, David, Zou, Yiyu, Platanias, Leonidas, Burgess, Laurence E., Pradhan, Kith, Steidl, Ulrich, Verma, Amit
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5398415/
https://ncbi.nlm.nih.gov/pubmed/27287719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-3062
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi